Skip to main content

Table 1 Baseline patient characteristics (n = 348)

From: Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy

Female sex, n (%) 126 (36)
Age [median (IQR)] years 50 (43 – 58)
Ethnicity Caucasian, n (%) 346 (99)
HCV genotype 1/2/3 (%) 240/25/83 (69/7/24)
ALT [median (IQR)] U/l 49 (28 – 86)
Hb [median (IQR)] g/dl 15.1 (14.2 – 16)
Creatinine [median (IQR)] mg/dl 0.8 (0.7 – 0.9)
EPO# [median (IQR)] mIU/ml* 7.8 (6 – 10.5)
Hepatitis activity mild, n (%) 170 (68)
Fibrosis absent or mild, n (%) 201 (81)
Severe Fibrosis or Cirrhosis1, n (%) 631 (18)
Steatosis absent or mild, n (%) 224 (90)
Initial daily RBV dose2, n (%)
  800 mg 37 (10)
  1.000 mg 125 (36)
  1.200 mg 110 (32)
  1.400 mg 76 (21)
PEG-IFN-α treatment, n (%)
  PEG-IFN-α2a 238 (68)
  PEG-IFN-α2b 1.0 μg/kg 30 (9)
  PEG-IFN-α2b 1.5 μg/kg 80 (23)
SVR by genotype 1/2/3, n (%) 101/20/68 (42/80/82)
EPO rs1617640 TT/TG/GG, n (%) 113/168/67 (33/48/19)
ITPA rs1127354 CC/CA/AA, n (%) 280/66/2 (80/19/1)
  1. Data are given as median and interquartile range, if not indicated otherwise. 249 patients undergone histological evaluation; #Pretreatment serum EPO measurement was available in 181 patients: *Normal range: 3.3-16.6 mIU/ml; 148 patients with histological signs of severe fibrosis or cirrhosis and 15 patients with clinical, biochemical and imaging evidence of severe fibrosis or cirrhosis. 2Initial daily RBV dose was weight-based on a sliding scale in subjects’ baseline weight. Abbreviations: HCV hepatitis C virus, γ-GT gamma-glutamyltransferase, ALT alanine transaminase, RBV ribavirin, PEG-IFN-α pegylated interferon-α, SVR sustained virological response, EPO erythropoietin, ITPA inosine triphosphatase.